The role of emerging therapy in the management of patients with diffuse low grade glioma

Document Type

Article

Publication Date

12-1-2015

Publication Title

Journal of neuro-oncology

Abstract

QUESTION: What is the role of immunotherapy/tumor vaccines in the treatment of low grade gliomas?

TARGET POPULATION: Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.

RECOMMENDATIONS: There is no evidence to support a recommendation in regards to the efficacy of immunotherapy or tumor vaccines for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess immunotherapies and tumor vaccines for low grade gliomas.

QUESTION: What is the role of nutrition in the treatment of low grade gliomas?

TARGET POPULATION: Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.

RECOMMENDATIONS: There was no evidence to support a recommendation in regard to the efficacy of nutritional therapy for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the efficacy of nutrition for this target population.

QUESTION: Is there a role for alternative or targeted therapies in the treatment of low grade gliomas?

TARGET POPULATION: Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.

RECOMMENDATION: There was no evidence to support a recommendation in regard to the efficacy of targeted or alternative agents for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess alternative and targeted therapies for this target population.

Medical Subject Headings

Brain Neoplasms; Complementary Therapies; Diet; Disease Management; Glioma; Humans; Neoplasm Grading

PubMed ID

26530260

Volume

125

Issue

3

First Page

631

Last Page

635

Find It @ Sladen

Share

COinS